Division of Infectious Disease, Wayne State University School of Medicine, USA
Review Article
Guardians of the Gut: Development and use of live biotherapeutic products for preventing recurrent Clostridioides difficile infection
Author(s): Astha Saini DO and Lea M Monday PharmD MD*
Clostridioides difficile infection (CDI) poses significant healthcare costs and morbidity due to its high recurrence rates. Reductions in gastrointestinal microbiome species heterogeneity from antibiotics or other causes result in a loss of colonization resistance that sets the stage for CDI. Antibiotics including vancomycin and fidaxomicin are the standard of care for primary and recurrent non-fulminant CDI (rCDI). Regardless of antibiotic choice, the likelihood of rCDI increases after each episode, and novel treatments are needed to prevent further recurrences. Microbiome research has led to the development of live biotherapeutic products (LBPs) to restore GI colonization resistance and break the cycle of rCDI. While derived from human stool, LBPs differ from fecal microbiota transplant (FMT) and one another. These agents vary in bacterial composition, manufacturing methods, adminis.. View More»
Spanish 
Chinese 
Russian 
German 
French 
Japanese 
Portuguese 
Hindi 